Assembly Biosciences is a clinical-stage biotechnology company developing oral small-molecule antivirals and related therapies for serious viral and liver diseases. Its pipeline has centered on candidates for recurrent genital herpes, hepatitis delta and hepatitis B, among other programs. The company partners and collaborates in virology research while advancing assets through early- and mid-stage clinical studies.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 9.6 | — | -10.2 | — |
| Q3 2025 | 10.8 | — | -9.2 | — |
| Q4 2025 | 42.5 | — | 22.1 | — |
| Q1 2026 | 8.2 | — | -9.1 | — |
| Q2 2026 | 13.4 | 38.9% | -3.9 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: DiaMedica Therapeutics Inc. (DMAC), AgomAb Therapeutics NV (AGMB), Citi Trends, Inc. (CTRN), Value Line, Inc. (VALU), Cerence Inc. (CRNC), Tectonic Therapeutic, Inc. (TECX)